LifeMine raises $263M in mission to improve organ transplant aftercare
Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
Foundayo clocked $98 million in sales in Q2, the first quarter it was available, compared to Novo’s $355 million for the same sales period.
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.
No deal between AstraZeneca and BMS, senior source insists: Reuters
Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal in pharma history.
Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees
Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the field.
Pfizer ramps up ongoing restructuring, Lisata axes 72% of staff
Follow along as BioSpace tracks job cuts and restructuring initiatives.
Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.
Novo dips 6% on Wegovy pill stumble despite Q2 earnings beat
Novo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.
Lisata axes 72% of workforce following failed merger with Kuva
In addition to laying off employees, including a member of its management team, Lisata Therapeutics is also suing Kuva Labs, alleging the company breached a merger agreement.